Mesa Laboratories, Inc. Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2021; filed June 1, 2021. The request metadata identifies “2019 Q4,” which does not match the supplied filing. This summary reflects the supplied fiscal 2021 Form 10-K, not a 2019 quarterly filing.
Business Context
Mesa Labs manufactures and sells quality-control products and services for regulated niche markets. Its four reportable segments are Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, and Continuous Monitoring. The company operates primarily in North America and Europe and sells through direct sales personnel and distributors.
Biopharmaceutical Development consists largely of the Gyros Protein Technologies acquisition, consolidated beginning November 1, 2019. The company exited its Cold Chain Packaging business during fiscal 2020.
Financial Performance and Liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $133.937 million | $117.687 million | 14% |
| Gross profit | $87.014 million | $65.362 million | 33% |
| Gross margin | 65.0% | 55.5% | Up 9.5 percentage points |
| Operating income | $12.358 million | $7.923 million | 56% |
| Operating margin | 9.2% | 6.7% | Improved |
| Net income | $3.274 million | $1.778 million | 84% |
| Diluted EPS | $0.64 | $0.41 | Improved |
| Cash flow from operations | $37.073 million | $26.988 million | 38% |
| Capital expenditures | $1.992 million | $1.498 million | 33% |
Product revenue was $107.028 million and service revenue was $26.909 million. Adjusted operating income, a non-GAAP measure excluding acquired-intangible amortization, stock-based compensation, and impairment, was $36.139 million versus $24.361 million in fiscal 2020.
Cash and cash equivalents were $263.865 million at March 31, 2021, compared with $81.380 million a year earlier. Working capital was $271.166 million versus $96.784 million. The company had no borrowings under its new revolving credit facility and stated that cash, operating cash flow, and $75 million of unused credit capacity should meet expected needs and potentially support acquisitions.
Debt consisted principally of $172.5 million of 1.375% convertible senior notes due August 15, 2025, carried at $145.675 million net of discounts and issuance costs. Total contractual obligations were $192.291 million, including the notes, interest, purchase commitments, and lease liabilities.
Segment Results and Material Changes
- Sterilization and Disinfection Control: Revenue increased 7% to $53.119 million; gross margin increased to 75% from 72%. Results benefited from volume, pricing, foreign exchange, operating efficiencies, and favorable mix.
- Instruments: Revenue declined 15% to $32.465 million as customers deferred discretionary capital purchases during the pandemic. Gross margin declined to 62% from 64%, partly due to $309,000 of consolidation costs and lower volume.
- Biopharmaceutical Development: Revenue increased to $33.892 million from $13.851 million, reflecting a full-year contribution from GPT. Gross margin increased to 62% from 3%; the prior-year margin was depressed by $8.502 million of GPT inventory step-up amortization.
- Continuous Monitoring: Revenue increased 5% to $14.461 million; gross margin increased to 41% from 33%, driven by business reorganization, operating efficiencies, product changes, and pricing.
- Operating expenses increased 30%, including higher selling, general and administrative, research and development, amortization, and stock-based compensation expenses associated in part with GPT.
- Nonoperating expense increased to $10.055 million, primarily because of interest and debt-discount amortization and foreign-currency losses, particularly related to the Swedish krona.
- The company raised $145.935 million net through a June 2020 equity offering of 690,000 shares and entered into a new $75 million revolving credit facility in March 2021.
- Backlog increased to approximately $11.3 million at March 31, 2021 from $10.1 million.
Outlook, Risks, and Unusual Items
Management expected demand to improve as pandemic restrictions eased and vaccine distribution progressed, although it cautioned that renewed outbreaks, facility restrictions, travel limitations, and customer capital-spending delays could continue to disrupt sales, installations, and service activity. Management expected Sterilization and Disinfection Control market expansion to resume in the first half of fiscal 2022 and anticipated continued organic growth opportunities in Biopharmaceutical Development and Continuous Monitoring.
Management expected fiscal 2022 selling expense to approximate 14% to 16% of revenue as it continued investing in sales and marketing. The filing does not provide formal revenue or earnings guidance.
- COVID-19 affected customer operations, laboratory utilization, discretionary purchases, on-site installations, travel, supply chains, and marketing activities.
- The company is consolidating its Butler, New Jersey manufacturing facility into Lakewood, Colorado. It recorded $588,000 of related costs and expected no material future costs.
- The company identified and corrected an immaterial ERP intercompany-elimination error, including a $429,000 fiscal 2020 adjustment that increased operating income and net income. Prior-period information was revised.
- GPT contributed $33.892 million of revenue and a $9.006 million net loss, including more than $8.9 million of acquired-intangible amortization and more than $3 million of foreign-currency losses.
- The company recorded a $2.714 million estimated sales-tax exposure related to GPT subsidiaries, including interest and penalties, and expected resolution during fiscal 2022.
- IBP contingent consideration of approximately $237,000 was expected to be paid after final milestones were achieved.
- Goodwill and other intangible assets totaled $272.6 million at March 31, 2021. Management concluded that no impairment existed, but impairment remains a material risk if operating performance, market conditions, or valuation assumptions deteriorate.
- The company expects to adopt ASU 2020-06 on April 1, 2021, removing the equity component and unamortized discount associated with the convertible notes and increasing beginning retained earnings by an estimated net historical interest effect of $7.293 million, subject to tax and other adjustments.
Investor Verification Checklist
- Verify that the intended filing period is fiscal 2021 rather than “2019 Q4.”
- Assess the sustainability of the 65% consolidated gross margin and the extent to which it reflects acquisition accounting, mix, foreign exchange, and temporary pandemic effects.
- Separate GPT’s recurring operating performance from acquisition-related amortization, inventory step-up effects, foreign-currency losses, and other nonrecurring items.
- Review liquidity relative to the $172.5 million convertible-note maturity in 2025, including potential conversion or repurchase obligations.
- Monitor COVID-19 effects on customer site access, discretionary capital spending, laboratory activity, supply chains, and installations.
- Evaluate the $2.714 million sales-tax contingency, the expected $237,000 IBP payment, and any additional acquisition-related obligations.
- Review goodwill and intangible-asset exposure, including the $14.930 million of estimated fiscal 2022 amortization expense.
- Confirm the effect of the ERP error correction and the planned adoption of ASU 2020-06 on reported earnings, equity, and debt presentation.
- Consider dilution from the 690,000-share equity offering, stock-based compensation, outstanding awards, and potential conversion of the senior notes.